Search Within

Myeloma

Formats
  1. Meeting Abstract (545)
  2. Journal Article (358)
  3. Review (36)
  4. Research Letter (20)
  5. Book Section (10)
  6. Guidelines (10)
  7. Correspondence (6)
  8. Editorial (5)
  9. Conference Paper (1)
Groups
  1. Center for Hematologic Malignancies (991)
  2. Department of Medicine (991)
  3. Hematologic Malignancies, Division of (991)
  4. Hematologic Malignancies Research (653)
  5. Survivorship Research (358)
  6. Sloan Kettering Institute Postdocs (293)

More Groups

People
  1. Alexander Lesokhin (365)
  2. Carl Landgren (336)
  3. Hani Hassoun (330)
  4. Sham Mailankody (284)
  5. Malin Hultcrantz (261)
  6. Heather Landau (240)

More People

Years
  1. 2025 (14)
  2. 2024 (71)
  3. 2023 (115)
  4. 2022 (96)
  5. 2021 (76)
  6. 2020 (95)

More Years

Publications
  1. Blood (305)
  2. Clinical Lymphoma, Myeloma and Leukemia (96)
  3. Journal of Clinical Oncology (85)
  4. Haematologica (41)
  5. Biology of Blood and Marrow Transplantation (29)
  6. Blood Cancer Journal (22)

More Publications

Publishers
  1. American Society of Hematology (326)
  2. Elsevier Inc. (159)
  3. American Society of Clinical Oncology (87)
  4. Nature Publishing Group (83)
  5. Ferrata Storti Foundation (41)
  6. American Association for Cancer Research (34)

More Publishers

Results (991)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies
    Journal Article

    Davila, M. L.; Bouhassira, D.; Park, J. H.; Curran, K. J.; Smith, E.; Pegram, H. J.; Brentjens, R.
    International Journal of Hematology (2014)

    Fulltext@MSK | Save
  • Current strategies for treatment of relapsed/refractory multiple myeloma
    Journal Article

    Laubach, J. P.; Voorhees, P. M.; Hassoun, H.; Jakubowiak, A.; Lonial, S.; Richardson, P. G.
    Expert Review of Hematology (2014)

    Fulltext@MSK | Save
  • T-cell depleted allogeneic HSCT for patients with relapsed, high-risk multiple myeloma permits long-lasting remissions in the absence of graft-versus-host disease and provides a platform for adoptive immunotherapeutic approaches
    Meeting Abstract

    Koehne, G.; Devlin, S.; Landau, H.; Hassoun, H.; Lesokhin, A. M.; Lendvai, N.; Chung, D. J.; Bravo, C.; Giralt, S. A.
    Biology of Blood and Marrow Transplantation (2014)

    Fulltext@MSK | Save
  • Phase 1 trial of carfilzomib + melphalan (CarMel) conditioning and autologous hematopoietic stem cell transplantation (AHSCT) for relapsed multiple myeloma (MM)
    Meeting Abstract

    Costa, L. J.; Landau, H.; Venkata, J. K.; Kang, Y. B.; Koehne, G.; Chung, D. J.; Lendvai, N.; Bentz, T.; Giralt, S. A.
    Biology of Blood and Marrow Transplantation (2014)

    Fulltext@MSK | Save
  • Immune reconstitution after autologous stem cell transplantation for multiple myeloma
    Meeting Abstract

    Chung, D. J.; Pronschinske, K. B.; Shyer, J. A.; Wu, V.; Hassoun, H.; Landau, H.; Lendvai, N.; Lesokhin, A. M.; Koehne, G.; Giralt, S. A.; more...
    Biology of Blood and Marrow Transplantation (2014)

    Fulltext@MSK | Save
  • Markers for anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) therapy in melanoma
    Journal Article

    Postow, M. A.; Yuan, J.; Kitano, S.; Lesokhin, A. M.; Wolchok, J. D.
    Methods in Molecular Biology (2014)

    Fulltext@MSK | Save
  • Peripheral blood and tumor biomarkers in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab
    Meeting Abstract

    Callahan, M. K.; Horak, C. E.; Curran, M. A.; Hollman, T.; Schaer, D. A.; Yuan, J.; Lesokhin, A. M.; Kitano, S.; Hong, Q.; Ariyan, C. E.; more...
    Journal for ImmunoTherapy of Cancer (2013)

    Fulltext@MSK | Save
  • Safety and clinical activity of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL)
    Meeting Abstract

    Wolchok, J. D.; Kluger, H. M.; Callahan, M. K.; Postow, M. A.; Gordon, R. A.; Segal, N. H.; Rizvi, N. A.; Lesokhin, A. M.; Reed, K.; Burke, M. M.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Results after long-term follow-up from the CAN2007 phase I/II study of weekly or twice-weekly bortezomib in patients (pts) with relapsed systemic light-chain (AL) amyloidosis
    Meeting Abstract

    Reece, D. E.; Hegenbart, U.; Sanchorawala, V.; Merlini, G.; Palladini, G.; Blade, J.; Fermand, J. P.; Hassoun, H.; Heffner, L.; Pei, L.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • A phase I dose-escalation study evaluating the effects of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with select relapsed or refractory hematologic malignancies
    Meeting Abstract

    Lesokhin, A. M.; Gutierrez, M.; Halwani, A. S.; Ansell, S. M.; Armand, P.; Borrello, I.; Segota, Z. E.; Cohen, A. D.; Talpaz, M.; Cattry, D.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save